<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710656</url>
  </required_header>
  <id_info>
    <org_study_id>MAGNIFICENT</org_study_id>
    <nct_id>NCT02710656</nct_id>
  </id_info>
  <brief_title>Study Comparing Legflow Versus Bare Balloon Angioplasty for Treatment of Atherosclerotic Disease</brief_title>
  <official_title>Multicenter Randomized Controlled Trial Comparing Legflow - DCB (Cardionovum) Versus Bare Balloon Angioplasty for the Treatment of Atherosclerotic Disease in the Superficial Femoral &amp; Popliteal Segment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardionovum GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archer Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardionovum GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized multicentric study for endovascular treatment of patients with obstructive&#xD;
      disease in the SFA (superficial femoral artery) and in the popliteal artery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This interventional study will collect data about the treatment of de novo lesions or&#xD;
      restenotic lesions. Restenotic lesions that are previously DCB (drug coated balloon) treated&#xD;
      or in-stent restenosis are excluded in this study.&#xD;
&#xD;
      The primary objective of this randomized study is to compare the efficacy of the DCB (Legflow&#xD;
      - Cardionovum) versus POBA for the treatment of de novo lesions or restenosis in the SFA and&#xD;
      in the popliteal artery (segment P1 -P2) by assessing the binary restenosis rate with duplex&#xD;
      ultrasonography at 12 months.&#xD;
&#xD;
      The secondary endpoints are the assessment of the immediate procedural outcome, distribution&#xD;
      of Rutherford, mortality, target lesion revascularization (TLR), target extremity&#xD;
      revascularization (TER), amputation and anklebrachial index (ABI).&#xD;
&#xD;
      For each patient enrolled, data will be collected up to 12 months after the procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy measured by binary restenosis rate</measure>
    <time_frame>Until 12 months after procedure</time_frame>
    <description>Binary restenosis rate determined by duplex ultrasonography at 1, 6 and 12 months afte procedure. Binary restenosis is defined as a re-obstruction ≥50% of the target lesion (peak systolic velocity ratio &gt; 2.4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate procedural outcome of percutaneous balloon angioplasty</measure>
    <time_frame>From start of procedure surgery until completion of procedure surgery (Percutaneous balloon angioplasty)</time_frame>
    <description>Investigator opinion of procedural and technical success of the percutaneous angioplasty. Opinion of investigator (yes/no) is recorded in the CRF for technical success and procedural success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford</measure>
    <time_frame>Baseline until 12 months after procedure</time_frame>
    <description>Distribution of Rutherford stages during follow-up as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Until 12 months after procedure</time_frame>
    <description>30-day mortality, 6-months mortality and overall mortality at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeated target lesion revascularization (TLR) rate</measure>
    <time_frame>Until 12 months after procedure</time_frame>
    <description>TLR is defined as a repeated procedure (endovascular or surgical) due to a problem arising from the lesion (+1 cm proximally and distally to include edge phenomena) initially treated in surviving patients with preserved limb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeated target extremity revascularization (TER) rate</measure>
    <time_frame>Until 12 months after procedure</time_frame>
    <description>TER is defined as a procedure (endovascular or surgical) due to a problem arising in the ipsilateral traject (iliac, femoropopliteal and below the knee arteries) remote from the lesion initially treated in surviving patients with preserved limb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor and major amputation rate</measure>
    <time_frame>Until 12 months after procedure</time_frame>
    <description>Occurrence of minor (below the ankle) and major (above the ankle) amputations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index (ABI)</measure>
    <time_frame>Baseline until 12 months after procedure</time_frame>
    <description>Reporting of Ankle-Brachial Index compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Drug Coated Balloon (DCB) - Legflow®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard PTA - POBA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Legflow® balloon</intervention_name>
    <description>Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel</description>
    <arm_group_label>Drug Coated Balloon (DCB) - Legflow®</arm_group_label>
    <other_name>Paclitaxel eluting balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard PTA</intervention_name>
    <description>Percutaneous angioplasty performed with a standard balloon</description>
    <arm_group_label>Standard PTA - POBA</arm_group_label>
    <other_name>POBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must sign the informed consent form prior to the index-procedure.&#xD;
&#xD;
          2. Patient must be older than 18 years.&#xD;
&#xD;
          3. Patient with Rutherford 2, 3 and 4..&#xD;
&#xD;
          4. Target lesion is an occlusion or ≥70% stenosis (visual estimate) located in SFA or&#xD;
             popliteal artery (P1 -P2).&#xD;
&#xD;
          5. Maximum length of the target lesion is 13 cm.&#xD;
&#xD;
          6. Target lesion is TASC A, B or C.&#xD;
&#xD;
          7. Target lesion is a de novo lesion or restenotic lesion (previously POBA treated,&#xD;
             in-stent restenosis is not allowed).&#xD;
&#xD;
          8. Inflow arteries are free from hemodynamically significant obstruction (i.e. ≥ 50%&#xD;
             diameter stenosis). It is allowed to treat inflow lesions during the index-procedure&#xD;
             if the result is ≤ 30% diameter stenosis (treatment with DCB or DES is not allowed).&#xD;
             Treatment of a non-target lesion in the target vessel is allowed if the nontarget&#xD;
             lesion is considered to be an inflow lesion.&#xD;
&#xD;
          9. Popliteal artery P3 segment (below knee popliteal artery) is free from hemodynamically&#xD;
             significant obstruction (i.e. ≥ 50%). Treatment of a lesion in this segment is not&#xD;
             allowed during the index-procedure.&#xD;
&#xD;
         10. At least 1 patent (&lt; 50% diameter stenosis) below-the-knee vessel (anterior tibial&#xD;
             artery, posterior tibial artery or peroneal artery) till the ankle as confirmed by&#xD;
             baseline angiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is already included in this study (recruitment of the contralateral leg is not&#xD;
             allowed).&#xD;
&#xD;
          2. Patient has a known intolerance to antiplatelet therapy or contrast agent.&#xD;
&#xD;
          3. Patient with known sensitivity to Paclitaxel.&#xD;
&#xD;
          4. Patient is pregnant or patient intends to become pregnant within 1 year after the&#xD;
             index-procedure.&#xD;
&#xD;
          5. Patient takes esomeprazole or omeprazole.&#xD;
&#xD;
          6. Patient with serum creatinine &gt;2.0 mg/dL or renal dialysis.&#xD;
&#xD;
          7. Patient suffers from acute limb ischemia defined as any sudden decrease in limb&#xD;
             perfusion causing a potential threat to limb viability.&#xD;
&#xD;
          8. Patient has a life expectancy &lt;2 years.&#xD;
&#xD;
          9. Patient with Rutherford 0, 1 , 5 and 6.&#xD;
&#xD;
         10. Patient has a target lesion that is severely calcified (grade 3 and grade 4).&#xD;
&#xD;
         11. Patient with a TASC D lesion.&#xD;
&#xD;
         12. Patient has an acute thrombus or aneurysm in the target vessel.&#xD;
&#xD;
         13. Patient has a target lesion that cannot be crossed with a guidewire.&#xD;
&#xD;
         14. Target vessel has been treated previously with a DCB or a DES.&#xD;
&#xD;
         15. Treatment of outflow lesions during the index-procedure.&#xD;
&#xD;
         16. Patients with significant disease of all 3 infrapopliteal vessels (i.e. ≥ 50% diameter&#xD;
             stenosis in each vessel).&#xD;
&#xD;
         17. Any scheduled surgery within 3 months after the index-procedure that would necessitate&#xD;
             the discontinuation of clopidogrel.&#xD;
&#xD;
         18. Patients with previous bypass surgery involving the SFA.&#xD;
&#xD;
         19. Patient has cirrhosis of the liver.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Goverde, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA Stuivenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL (Ziekenhuis Oost-Limburg)</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa hospital</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeau</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Cermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Mont-de-Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Arnsberg</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>SFA</keyword>
  <keyword>Poplitea</keyword>
  <keyword>Drug coated balloon</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Restenosis</keyword>
  <keyword>Peripheral artery disease (PAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

